A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort
Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, Yogen Saunthararajah, Kira Gritsman, Alejandro Sica, Noah Kornblum, Nishi Shah, David Levitz, Bradley Rockwell, Lauren Shapiro, Ridhi Gupta, Kith Pradhan, Xiaonan Xue, Anne Munoz, Aradhika Dhawan, Karen Fehn, Monica Comas, Jhannine Verceles, Brian A. Jonas, Suman Kambhampati, Yang Shi, Ira Braunschweig, Dennis Cooper, Marina Konopleva, Eric J. Feldman, Amit Verma
Abstract
ABSTRACT: A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median overall survival for patients with acute myeloid leukemia and a TP53-mutation was 16.1 and 11.3 months, respectively. This trial was registered at www.clinicaltrials.gov as #NCT05184842.